$33.50
10.74% today
Nasdaq, Feb 28, 09:18 pm CET
ISIN
US61023L1089
Symbol
MNPR
Sector
Industry

Monopar Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Monopar Therapeutics Inc Classifications & Recommendation:

Buy
100%

Monopar Therapeutics Inc Price Target

Target Price $55.20
Price $30.25
Potential
Number of Estimates 5
5 Analysts have issued a price target Monopar Therapeutics Inc 2026 . The average Monopar Therapeutics Inc target price is $55.20. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 5 analysts: 5 Analysts recommend Monopar Therapeutics Inc to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Monopar Therapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the Monopar Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -3.04 -0.58
26.39% 80.92%
P/E negative

1 Analysts have issued a Monopar Therapeutics Inc forecast for earnings per share. The average Monopar Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.58
Unlock
. This is
70.71% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.58 70.71%
Unlock
, the lowest is
$-0.58 70.71%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-3.04 26.39%
2024
$-0.58 80.92%
Unlock
2025
$-3.46 496.55%
Unlock
2026
$-3.95 14.16%
Unlock
2027
$-3.69 6.58%
Unlock
2028
$-2.43 34.15%
Unlock

P/E ratio

Current -15.26 733.88%
2024
-52.16 241.81%
Unlock
2025
-8.74 83.24%
Unlock
2026
-7.66 12.36%
Unlock
2027
-8.20 7.05%
Unlock
2028
-12.45 51.83%
Unlock

Current Monopar Therapeutics Inc Upgrades & Downgrades Beta

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co. Locked ➜ Locked Locked Jan 22 2025
Piper Sandler Locked ➜ Locked Locked Jan 10 2025
HC Wainwright & Co. Locked ➜ Locked Locked Nov 11 2024
Rodman & Renshaw Locked ➜ Locked Locked Oct 11 2024
Analyst Rating Date
Locked
HC Wainwright & Co.: Locked ➜ Locked
Jan 22 2025
Locked
Piper Sandler: Locked ➜ Locked
Jan 10 2025
Locked
HC Wainwright & Co.: Locked ➜ Locked
Nov 11 2024
Locked
Rodman & Renshaw: Locked ➜ Locked
Oct 11 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today